Abstract 929P
Background
The incidence of Laryngeal Squamous Cell Carcinoma (LSCC) has increased over the past 30 years, presenting new challenges in the management of this disease. In response to these evolving needs, we developed a machine learning (ML) prognostic model to optimize the treatment strategies for patients diagnosed with advanced LSCC.
Methods
Data from 2000 to 2020 were obtained from the SEER database. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test was used to compare variables. The Kaplan-Meier estimator, log-rank test, and Cox regression analysis identified prognostic factors for overall survival (OS) and cancer-specific survival (CSS). We constructed prognostic models using ML algorithms to predict 5-year survival. The data were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
A total of 7,350 patients were included: 2,689 with glottic (GC), 4,349 with supraglottic (SuGC), and 312 with subglottic (SG) cancers. The median patient age was 60 years. A total of 88.8% of the patients had a T3 and T4. The largest racial group was white, comprising 74.8% of the cases, and 21.1% of the cases were black. Most cases were stage IV AJCC (89.5%), and 41.4% of the patients had N2. Of the patients, 52% underwent total laryngectomy, which was the most common surgical procedure (39.1%). ML was used to identify the most important features of GC, including age, sex, and AJCC staging. Age and sex were considered as key factors for SuGC metastasis. For SC, the most important features identified were surgery combined with radiotherapy, sex, and surgery combined with chemoradiotherapy.
Conclusions
This study presents ML models tailored to three anatomical sites of LSCC. Key factors such as age and sex for GC and SuGC and treatment combinations for SG. These models underscore their utility in personalized medicine, enabling clinicians to customize treatment strategies based on individual characteristics and improve clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
Presenter: Yi Hu
Session: Poster session 03
Resources:
Abstract
1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Presenter: Michel Obeid
Session: Poster session 03
1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 03
1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study
Presenter: Mariam Shalaby
Session: Poster session 03
1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Presenter: Sarah Roffeis
Session: Poster session 03
1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors
Presenter: Antoine Italiano
Session: Poster session 03
Resources:
Abstract
1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures
Presenter: Elisabetta Nale
Session: Poster session 03
1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Abdulrahman Alghabban
Session: Poster session 03
1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Presenter: Mariano Provencio Pulla
Session: Poster session 03
1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Presenter: Annarita Avanzo
Session: Poster session 03